Practice Points in TGCT: Updates on Safe Use of Novel Systemic Options
0.25 hr(s) | ABIM , CME , MOC , Royal College of Physicians and Surgeons of Canada
Therapeutic Area(s): Oncology
Release Date: January 13, 2022
Expiration Date: January 12, 2023
Location: Internet Activity Enduring
Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors.